Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Companyâs technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Companyâs laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
髿é·
å瀟ã®åçã¯éå»3幎éã«ãããçå®ã«å¢å ããŠããã幎平åã§58.25%ã®æé·çã瀺ããŠããŸãã
æé·äž
åç€Ÿã¯æé·ãã§ãŒãºã«ãããææ°ã®å¹Žéåçã¯USD 24.05Mã«éããŠããŸãã
å²å®
åç€Ÿã®ææ°ã®PEã¯-53.61ã§ãéå»3幎éã®æ°Žæºãšæ¯èŒããŠå®å€åã«ãããŸãã
æ©é¢æè³å®¶ã®å£²ãè¶ã
ææ°ã®æ©é¢æè³å®¶ã®ä¿ææ ªæ°ã¯341.74Kæ ªã§ãåååææ¯ã§7.77%æžå°ããŠããŸãã
ãžã§ãŒã ãºã»ã·ã¢ã³ãºãä¿æ
ã¹ã¿ãŒæè³å®¶ãžã§ãŒã ãºã»ã·ã¢ã³ãºã¯æ¬éæã0.00æ ªä¿æããŠããŸãã
åžå ޿޻åãæŽ»çº
å瀟ãžã®æè³å®¶ã®é¢å¿ãé«ãŸã£ãŠããã20æ¥éã®å£²è²·å転çã¯4.66ã§ãã